These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 11705862)

  • 1. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
    Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
    Ozdemir E; Kakehi Y; Okuno H; Yoshida O
    J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
    Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
    J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K; Turpeenniemi-Hujanen T
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
    Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
    Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.